fr

A.I.O.

This Week In Medicine

Welcome to This Week in Medicine - Your Filtered Medical Journal SummaryLooking to stay up-to-date with the latest medical research but short on time? This Week in Medicine has you covered! Our AI generated podcast provides you with a convenient, on-the-go solution to keep you informed about the most significant developments in the medicine field. We understand that your time is valuable, so we've done the hard work for you. Each episode offers a filtered and concentrated summary of key journal articles, allowing you to stay informed without the need to sift through pages of research papers. W...

N'hésitez pas à visiter le site du podcast et à soutenir son créateur : redcircle.com

Auteur

A.I.O.

Catégorie

Health

Site du podcast

redcircle.com

Dernier épisode

19 nov. 2026

Où écouter ?

Les podcasts dans l'appli Replaio Radio Bientôt disponible

Les podcasts arrivent très bientôt dans l'appli. Installe-la dès maintenant et découvre en avant-première une toute nouvelle façon de vivre les podcasts

Télécharger sur Google Play Installe-la gratuitement Android 10 M+ de téléchargements · note de 4,7+ iOS bientôt

Épisodes

JAMA November 2026 Medical Imaging and Pediatric and Adolescent Brain Tumor Risk 19.11.2026

This retrospective study investigated the relationship between  ionizing radiation from medical imaging  and the subsequent development of  brain tumors  in a massive cohort of young patients. By analyzing healthcare data from millions of children across the United States and Canada, researchers tracked cumulative radiation dosages and diagnosed brain tumor outcomes over many years. The findings r...

JAMA November 2026 Plasma eMTBR-tau as a Biomarker for Chronic Traumatic Encephalopathy Tau Tangle Neuropathology 19.11.2026

Chronic traumatic encephalopathy remains notoriously difficult to identify during a patient's lifetime due to a lack of reliable living diagnostic indicators. To address this limitation, researchers recently investigated whether a specific blood protein known as  plasma eMTBR-tau  could serve as an effective screening marker for the degenerative brain condition. By analyzing blood samples from...

NEJM November 19 2026 19.11.2026

Researchers in China conducted a randomized trial to determine if  mechanical thrombectomy  remains beneficial for certain acute ischemic stroke victims when performed between  24 and 72 hours  after symptoms begin. The study evaluated patients with  large-vessel occlusions  and salvageable brain tissue, comparing those who received endovascular therapy alongside standard care against a control gr...

NEJM November 19 2026 Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI 19.11.2026

A recent Japanese clinical trial investigated whether  omitting aspirin  during emergency angioplasty for severe heart attacks is safe for patients. Researchers randomly assigned over two thousand individuals with  ST-segment elevation myocardial infarction  to receive either  prasugrel monotherapy  or traditional  dual antiplatelet therapy  for a full year. The primary goal was to determine if th...

NEJM November 19 2026 Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer 19.11.2026

A  phase 3 clinical trial  conducted in China evaluated the combination of  anbenitamab and HB1801  against the standard treatment of docetaxel, trastuzumab, and pertuzumab (THP) for patients suffering from  HER2-positive advanced breast cancer . The study randomly assigned 885 participants to receive one of the two therapies to compare their  progression-free survival  and response rates. Interim...

NEJM November 12 2026 Prasugrel versus Ticagrelor in Acute Coronary Syndromes 16.11.2026

Medical researchers in Sweden conducted a  cluster-randomized trial  involving over 17,000 adults to determine whether  prasugrel  or  ticagrelor  is the superior blood-thinning medication for patients recovering from a heart procedure related to  acute coronary syndromes . By shifting entire regional healthcare policies between the two drugs over a three-year period, the study tracked the one-yea...

NEJM November 12 2026 Prevention of Venous Thromboembolism after Total Hip or Knee Replacement 16.11.2026

A recent clinical trial investigated the  prevention of blood clots following elective hip or knee replacement surgeries by comparing three different medications:  aspirin, warfarin, and rivaroxaban . Over a thirty-day treatment period, nearly  eighteen thousand patients  were randomly assigned to one of these three drug regimens, with outcomes monitored for half a year. Researchers assessed both ...

NEJM November 12 2026 Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty 16.11.2026

A recent  multicenter clinical trial  investigated whether taking  aspirin alone  is as effective as starting with  rivaroxaban  before transitioning to aspirin for preventing dangerous blood clots following  hip and knee replacement surgeries . Researchers randomly assigned over  five thousand patients  to receive either the single-drug aspirin regimen or the combined rivaroxaban-then-aspirin tre...

NEJM November 5, 2026 Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis 05.11.2026

Recent clinical research evaluated the effectiveness of plozasiran, an innovative RNA-based therapy, in treating individuals diagnosed with severe hypertriglyceridemia. Across two closely monitored trials involving 757 participants, patients received either the targeted medication or a placebo to measure changes in fasting lipid levels over a one-year period. The findings revealed that administrat...

NEJM November 5, 2026 Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain 05.11.2026

A recent clinical trial investigated whether performing computed tomographic (CT) coronary angiography could lower the long-term risk of heart-related complications in emergency department patients whose heart attacks were initially excluded. Researchers across the United Kingdom monitored over 3,100 intermediate-risk participants who were randomly split to receive either specialized CT imaging or...

NEJM November 5 , 20026 Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity 05.11.2026

A recent clinical trial investigated the effectiveness of retatrutide, an innovative triple-hormone receptor agonist, for managing obesity in adults. Over an eighty-week period, participants received weekly injections of the medication or a placebo to measure changes in body weight, knee osteoarthritis pain, and obstructive sleep apnea severity. The findings revealed that individuals treated with...

JAMA October 2026 Risk-Based vs Annual Breast Cancer Screening The WISDOM Randomized Clinical Trial 29.10.2026

A large-scale clinical trial involving more than 28,000 women was conducted to evaluate whether risk-based breast cancer screening serves as a viable substitute for traditional annual mammography. By utilizing genetic testing, polygenic risk scores, and clinical models, participants in the experimental group were assigned customized screening schedules tailored to their specific vulnerability leve...

JAMA October 2026 Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer The HORIZON-Breast06 Randomized Clinical Trial 29.10.2026

The HORIZON-Breast06 clinical trial investigated the effectiveness of trastuzumab rezetecan compared to standard chemotherapy for individuals suffering from ERBB2-low advanced breast cancer. Conducted across numerous medical centers in China, the multi-center study randomly divided 551 eligible participants into two distinct treatment groups. The primary focus of the research was to measure progre...

NEJM Oct 22 2026 Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis 28.10.2026

A recent international clinical trial investigated whether shortening antibiotic regimens for left-sided infective endocarditis is safe and effective once patients achieve clinical stability. Researchers compared a response-tailored strategy—which stopped antibiotics earlier—against the standard six-week duration across more than 500 participants. The findings revealed that the tailored approachsu...

NEJM Oct 22 2026 Ianalumab for the Treatment of Patients with Sjögren’s Disease 28.10.2026

Two clinical studies, NEPTUNUS-1 and NEPTUNUS-2, evaluated the effectiveness of the antibody ianalumab as a potential medical intervention for Sjögren's disease, a complicated autoimmune condition lacking specialized treatments. Researchers divided hundreds of participants into groups to compare monthly or quarterly subcutaneous injections of the medication against a placebo over the course of...

NEJM Oct 22 2026 Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event 28.10.2026

A recent clinical trial investigated whether the medication milvexian could safely lower the chances of secondary heart attacks and strokes in individuals recovering from acute coronary syndrome. Researchers administered either milvexian or a placebo alongside standard antiplatelet treatments to over fourteen thousand participants in this global study. Ultimately, the investigation was halted earl...

JAMA October 2026 Out-of-Pocket Costs for Chronic Illness Management in High-Deductible Health Plans 13.10.2026

A recent retrospective study examined out-of-pocket expenses for working-age adults managing common chronic conditions like diabetes and hypertension. Researchers analyzed national commercial insurance claims from 2022 to 2023 to compare financial burdens between high-deductible health plans and traditional coverage. The findings revealed that patients enrolled in high-deductible policiesfaced ann...

JAMA October 2026 Patient Navigation Plus mHealth Incentives for Linkage to OUD Care for Adults Who Also Use Methamphetamines A Pilot Randomized Clinical Trial 13.10.2026

This clinical trial investigated a mobile health strategy combined with patient navigation to improve outpatient care for hospitalized adults struggling with both opioid use disorder and methamphetamine use. Researchers randomly assigned participants to receive either standard treatment or an intervention featuring financial rewards for medication adherence and dedicated support during the first m...

JAMA October 2026 Digital and Coaching Interventions for Uptake of Cancer Genetic Testing The MiGHT Randomized Clinical Trial 13.10.2026

The Michigan Genetic Hereditary Testing trial explored how to increase low completion rates for hereditary cancer genetic testing. Researchers evaluated nearly eight hundred adult participants who qualified for genetic evaluation across three different groups. Individuals were randomly assigned to receive either telephone-based health coaching, a self-directed digital tool, or standard care. The f...

JAMA Cardiology October 2026 Global, Regional, and National Burden of Heart Failure, 1990-2023 A Systematic Analysis for the Global Burden of Disease Study 2023 12.10.2026

A recent cross-sectional analysis utilizing Global Burden of Disease methodologies evaluates the worldwide impact and underlying causes of heart failure across 204 countries and territories from 1990 to 2023. By synthesizing extensive data, the research revealed an estimated 56.0 million cases globally in 2023, with prevalence rates consistently rising alongside advancing age. The study highlights...

JAMA Cardiology October 2026 Intensive vs Standard Blood Pressure Lowering in People With and Without Chronic Kidney Disease 12.10.2026

 recent systematic review and meta-analysis investigated how aggressively reducing blood pressure impacts heart health and renal function in adults. By examining twenty-seven randomized trials encompassing nearly ninety thousand participants, researchers compared intensive and standard blood pressure management strategies. The findings revealed that aggressive blood pressure reduction significantl...

JAMA October 2026 Development and Validation of an Adult Medical Urgency Score for US Donor Heart Allocation 12.10.2026

A recent observational study utilized registry data from adult heart transplant candidates to create and validate the US Candidate Risk Score (US-CRS) as a replacement for the current six-status allocation framework. This new quantitative model relies on specific laboratory values and mechanical support devices to more accurately assess a patient's risk of mortality while waiting for an organ....

JAMA October 2026 Advance Care Planning for Black and White Older Adults With Serious Illness The EQUAL ACP Randomized Trial 09.10.2026

The EQUAL ACP randomized trial investigated whether facilitated advance care planning outperforms self-guided methods for seriously ill older adults. Researchers evaluated completion rates over one year among nearly eight hundred Black and White participants aged sixty-five and older across multiple Southern clinics. Overall results indicated no statistically significant difference in completion b...

JAMA October 2026 Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease The NOPARK Randomized Clinical Trial 09.10.2026

A recent phase 3 clinical trial investigated whether the supplement nicotinamide riboside could slow the progression of early-stage Parkinson disease. Researchers across eleven centers in Norway administered either the substance or a placebo to 393 participants over a 52-week period. To measure disease severity, the study tracked changes using standard movement and non-motor symptom scales. Ultima...

NEJM 10 8 2026 Vasopressors or Fluids in Early Septic Shock 09.10.2026

Vasopressors or Fluids in Early Septic Shock

Écoute le podcast This Week In Medicine sur Replaio

La radio et les podcasts dans une seule appli - gratuite, sans inscription. Installe-la dès aujourd'hui et ne rate pas le lancement

Télécharger sur Google Play

Replaio n'est pas éditeur de podcasts ; les noms des émissions, les visuels et l'audio appartiennent à leurs auteurs et sont diffusés via des flux RSS publics